Assistant Professor of Oncology
Luigi Marchionni is Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA. He is also co-PI of the Center for Computational Genomics at Johns Hopkins, a multi-disciplinary initiative that has been awarded competitive funding from the University leadership, including the Provost and President’s offices, to support research and education in the field of Computational Genomics.
Dr Marchionni is a skilled Bioinformaticist with extensive experience in the analysis and interpretation of genome-wide data. He trained in Medicine at the University of Turin, Italy, and obtained his PhD degree in “Structural and Functional Genomics” at the International School for Advanced Studies (ISAS-SISSA), Trieste, Italy. During his training, Dr Marchionni had the chance to collaborate with several research institutes, including the FIRC Institute for Molecular Oncology (IFOM, Milan), the RIKEN Genome Science Laboratory (Tsukuba and Yokohama, Japan) and the National Laboratory of the Italian Interuniversity Consortium for Biotechnologies (LNCIB, Trieste). In the past, Dr Marchionni major research activities focused on DNA sequences annotation, and the development of novel methods for gene expression profiling analysis. As a member of the FANTOM Consortium, Dr Marchionni was also actively involved in the annotation of the mouse transcriptome and in the implementation of the associated database. During his post-doctoral training Dr Marchionni joined the group of Dr Parmigiani, in the Oncology Biostatistics Division at Johns Hopkins, where he developed novel approaches to microarray data annotation and analysis, and prepared a systematic review to assess the evidence that the use of gene expression based assays improves prognostic prediction, treatment choice and health outcomes in women newly diagnosed with early stage breast cancer. Dr Marchionni is currently working on several large-scale genomics projects that are poised to generate novel methods of genomic analysis. His current research in particular focuses on knowledge integration across different genomics fields of investigation like gene expression and sequence analysis, as well as on gene expression data comparison across different platforms, laboratories, and species, to uncovering genetic contributions to relevant disease phenotypes, with a specific focus on biomarker discovery. In addition, Dr Marchionni has a strong interest in BPH, and to that end, he is leading a multidisciplinary research program aimed towards building the molecular understanding of epidemiologically important BPH pathways, through the integration of genomic data analysis and “proof-of-principle” experimental validation in laboratory models.
Marchionni, L.; Wilson, R.F.; Wolff, A.C.; Marinopoulos, S.; Parmigiani, G.; Bass, E.B.; Goodman, S.N. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008 Mar 4;148(5):358-369.
Schaeffer, E.M.; Marchionni, L.; Huang, Z.; Simons, B.; Blackman, A.; Yu, W.; Parmigiani, G.; Berman, D.M. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008 Dec 4;27(57):7180-7191.
Daniel, V.C.; Marchionni, L.; Hierman, J.S.; Rhodes, J.T.; Devereux, W.L.; Rudin, C.M.; Yung, R.; Parmigiani, G.; Dorsch, M.; Peacock, C.D.; Watkins, D.N. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009 Apr 15;69(8):3364-3373.
He, X.; Marchionni, L.; Hansel, D.E.; Yu, W.; Sood, A.; Yang, J.; Parmigiani, G.; Matsui, W.; Berman, D.M. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells. 2009 Jul;27(7):1487-1495.
Kachhap, S.K.; Rosmus, N.; Collis, S.J.; Kortenhorst, M.S.; Wissing, M.D.; Hedayati, M.; Shabbeer, S.; Mendonca, J.; Deangelis, J.; Marchionni, L.; Lin, J.; Hoti, N.; Nortier, J.W.; DeWeese, T.L.; Hammers, H.; Carducci, M.A. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 2010;5(6):e11208.
Noonan, K.; Marchionni, L.; Anderson, J.; Pardoll, D.; Roodman, G.D.; Borrello, I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood. 2010 Nov 4;116(18):3554-3563.
Ross, A.E.; Emadi, A.; Marchionni, L.; Hurley, P.J.; Simons, B.W.; Schaeffer, E.M.; Vuica-Ross, M. Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity. BJU Int. 2010 Dec 22.
Schreck, K.C.; Taylor, P.; Marchionni, L.; Gopalakrishnan, V.; Bar, E.E.; Gaiano, N.; Eberhart, C.G. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res. 2010 Dec 15;16(24):6060-6070